Intravitreal tigecycline treatment in experimental Acinetobacter baumannii endophthalmitis.

Abstract

PURPOSE:

To investigate the clinical and microbiological effectivity of intravitreal tigecycline in an experimental rabbit endophthalmitis model caused by imipenem resistant Acinetobacter baumannii.

MATERIALS AND METHODS:

Forty-eight eyes of 24 New Zealand white albino rabbits were divided into six groups (n=8 in each). The right eyes were divided into three groups and defined as infected group; left eyes were divided into three groups and defined as uninfected group. Infected group received 0.1 ml intravitreal A. baumannii suspension. Twenty-four hours after bacterial inoculation, group 1 received 1 mg/0.1 ml tigecycline and group 2 received 0.5 mg/0.1 ml tigecycline. Group 3 eyes received no treatment. In group 4, 0.1 ml of saline solution was injected. Groups 5 and 6 were received intravitreal tigecycline injection of 1 mg/0.1 ml and 0.5 mg/0.1 ml respectively. The eyes were enucleated for histopathological evaluation on the sixth day. Clinical and histological scoring systems were used to evaluate clinical and histological severity of the intraocular infection.

RESULTS:

The mean clinical scores of the six groups at the sixth day were 11±1.92, 12.4±6.2, 8.5±2.7, 0, 3±1.3, and 3±1.4 respectively. Mean histopathological scores were 7.8±2.8, 7.0±1.5, 5.6±1.4, 0, 0, and 0 respectively. There was no significant difference in mean clinical and histopathological scores of infected group (groups 1, 2 and 3). There was significant difference in mean clinical scores of groups 5 and 6 compared with group 4. Groups 4, 5 and 6 showed normal histological structure in histopathological evaluation and showed no significant difference. Microbiological cure was achieved in all infected eyes.

CONCLUSIONS:

Experimental rabbit endophthalmitis model caused by imipenem resistant A. baumannii was microbiologically cured by intravitreal tigecycline injection. However, a hypersensitivity-like reaction due to intravitreal application of tigecycline limits the use of this antimicrobial agent in A. baumannii endophthalmitis.

• Authors: Fatih Horozoglu, Gokhan Metan, Ozkan Sever, Duygu Percin, Cumhur S Topal, Tansu Gonen, Kadircan H Keskinbora, Birol Topcu, Ates Yanyali
• Journal: Journal of chemotherapy (Florence, Italy) (J Chemother) Vol. 24 Issue 2 Pg. 101-6 (Apr 2012) ISSN: 1973-9478 [Electronic] England
• PMID: 22546766 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Bacterial Agents
• Tigecycline
• Minocycline

Topics

• Acinetobacter Infections (drug therapy, microbiology)
• Acinetobacter baumannii (drug effects, isolation & purification)
• Animals
• Anti-Bacterial Agents (administration & dosage, pharmacology)
• Disease Models, Animal
• Endophthalmitis (drug therapy, microbiology, pathology)
• Eye Infections, Bacterial (drug therapy, microbiology, pathology)
• Female
• Humans
• Intravitreal Injections
• Male
• Minocycline (administration & dosage, analogs & derivatives, pharmacology)
• Rabbits
• Tigecycline
• Treatment Outcome